NCT05952557: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 5 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05952557 |
|---|---|
| Title | CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 5, 2023 |
| Completion date | March 4, 2030 |
| Required reporting date | March 4, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | None |